Tarsus Pharmaceuticals
NASDAQ: TARSFounded 2017 · Incorporated in Delaware · 440 employees on LinkedIn · 5 known investors
Tarsus Rx is a pharmaceutical company developing treatments for diseases with high unmet need, with a lead product XDEMVY (lotilaner ophthalmic solution) approved by the FDA for Demodex blepharitis. It maintains a pipeline of therapies targeting large disease categories with limited treatment options.
Founders & leadership
Tarsus Pharmaceuticals was founded in 2017 by Bobak Azamian, MD, PhD.
BA
Bobak Azamian, MD, PhDinFounder · ChairmanBobak Azamian, an MD and PhD trained physician and scientist, co-founded Tarsus Pharmaceuticals in 2016 and serves as its Chairman and CEO. The company develops treatments for diseases with high unmet need and launched XDEMVY, an FDA-approved therapy for Demodex blepharitis, while advancing a pipeline spanning conditions such as ocular rosacea and Lyme disease prevention.
Investors · 5
Frequently asked questions
- What does Tarsus Pharmaceuticals do?
- Tarsus Rx is a pharmaceutical company developing treatments for diseases with high unmet need, with a lead product XDEMVY (lotilaner ophthalmic solution) approved by the FDA for Demodex blepharitis. It maintains a pipeline of therapies targeting large disease categories with limited treatment options.
- Who founded Tarsus Pharmaceuticals?
- Tarsus Pharmaceuticals was founded by Bobak Azamian, MD, PhD in 2017.
- Who are Tarsus Pharmaceuticals's investors?
- Tarsus Pharmaceuticals's investors include APERTURE Venture Partners, Flying L Partners, Frazier Life Sciences, Visionary Ventures, Vivo Capital.